Enliven Therapeutics (NASDAQ:ELVN – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at Guggenheim in a research note issued to investors on Friday, Benzinga reports. They presently have a $78.00 target price on the stock. Guggenheim‘s price target would suggest a potential upside of 60.13% from the stock’s current price.
A number of other equities research analysts have also recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Thursday, October 15th. Zacks Research downgraded Enliven Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 13th. HC Wainwright lifted their price objective on Enliven Therapeutics from $65.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, October 19th. Mizuho boosted their price objective on Enliven Therapeutics from $62.00 to $73.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 18th. Finally, Barclays started coverage on Enliven Therapeutics in a research report on Tuesday, August 18th. They set an “overweight” rating and a $78.00 price objective for the company. Ten investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $75.44.
View Our Latest Stock Analysis on ELVN
Enliven Therapeutics Price Performance
Shares of NASDAQ ELVN traded up $3.92 during trading hours on Friday, hitting $48.71. 236,893 shares of the stock were exchanged, compared to its average volume of 1,299,503. Enliven Therapeutics has a one year low of $14.78 and a one year high of $62.32. The company’s 50 day moving average is $47.48 and its 200 day moving average is $42.96. The firm has a market capitalization of $3.57 billion, a P/E ratio of -29.13 and a beta of 0.34.
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.09. Research analysts anticipate that Enliven Therapeutics will post -1.79 earnings per share for the current fiscal year.
Insider Buying and Selling at Enliven Therapeutics
In related news, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction on Monday, October 19th. The shares were sold at an average price of $38.48, for a total transaction of $231,572.64. Following the transaction, the chief financial officer owned 38,000 shares of the company’s stock, valued at approximately $1,462,240. The trade was a 13.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director J. Scott Garland sold 13,000 shares of the company’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $46.67, for a total transaction of $606,710.00. Following the transaction, the director owned 13,000 shares of the company’s stock, valued at approximately $606,710. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 31,054 shares of company stock worth $1,493,823. 3.00% of the stock is currently owned by corporate insiders.
Institutional Trading of Enliven Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new position in shares of Enliven Therapeutics during the 2nd quarter worth about $221,255,000. First Light Asset Management LLC raised its position in shares of Enliven Therapeutics by 574.1% during the second quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company’s stock valued at $69,058,000 after buying an additional 1,158,883 shares during the last quarter. Pictet Asset Management Holding SA raised its position in shares of Enliven Therapeutics by 14.1% during the third quarter. Pictet Asset Management Holding SA now owns 1,325,740 shares of the company’s stock valued at $60,772,000 after buying an additional 163,956 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Enliven Therapeutics by 276.4% in the third quarter. Assenagon Asset Management S.A. now owns 1,153,973 shares of the company’s stock valued at $52,898,000 after buying an additional 847,399 shares during the period. Finally, Rock Springs Capital Management LP lifted its stake in shares of Enliven Therapeutics by 3.5% in the first quarter. Rock Springs Capital Management LP now owns 826,500 shares of the company’s stock valued at $32,399,000 after buying an additional 28,095 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.
About Enliven Therapeutics
Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.
Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.
Read More
- Five stocks we like better than Enliven Therapeutics
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
- Block by Block: Cash App Builds a Stronger Foundation
- Arista Networks Cashes In on the AI Infrastructure Buildout
- Powering Up: Freeport-McMoRan’s $4.5B Copper Expansion
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
